Article Text
Abstract
During the 1970s, prenatal screening technologies were in their infancy, but were being swiftly harnessed to uncover and prevent spina bifida. The historical rise of this screening process and prevention programme is analysed in this paper, and the role of ethical debates in key studies, editorials and letters reported in the Lancet, and other related texts and governmental documents between 1972 and 1983, is considered. The silence that surrounded rigorous ethical debate served to highlight where discussion lay—namely, within the justifications offered for the prevention of spina bifida, and the efficacy and benefits of screening. In other words, the ethical justification for screening and prevention of spina bifida, when the authors are not explicitly interested in ethics, is considered. These justifications held certain notions of disability as costly to society, with an imperative to screen and prevent spina bifida for the good of the society.
- AFP, α-fetoprotein
- DHSS, Department of Health and Social Security
- NHS, National Health Service
Statistics from Altmetric.com
Footnotes
-
Competing interests: None.
Read the full text or download the PDF:
Other content recommended for you
- Primary prevention of neurological illness early in life
- Prevalence and timing of pregnancy termination for brain malformations
- Sickle cell disease and thalassaemia antenatal screening programme in England over 10 years: a review from 2007/2008 to 2016/2017
- Fetal cardiac screening: why bother?
- Prepregnancy care
- Epidemic preparedness: Prenatal Zika virus screening during the next epidemic
- Strategies for antenatal detection of Down’s syndrome
- Socioeconomic inequalities in outcome of pregnancy and neonatal mortality associated with congenital anomalies: population based study
- Socioeconomic inequalities in pregnancy outcome associated with Down syndrome: a population-based study
- Adverse pregnancy outcomes around incinerators and crematoriums in Cumbria, north west England, 1956–93